academic article

• Plasma Ceramides and Sphingomyelins and Sudden Cardiac Death in the Cardiovascular Health Study..  JAMA network open.  6:-. 2023
• Evaluation of plasma sphingolipids as mediators of the relationship between kidney disease and cardiovascular events..  EBioMedicine.  -. 2023
• High-Density Lipoprotein Lipidomics and Mortality in CKD..  Kidney medicine.  5:-. 2023
• High-Density Lipoprotein Lipidomics in Chronic Kidney Disease..  Clinical chemistry.  69:273-282. 2023
• Circulating ceramides and sphingomyelins and the risk of incident cardiovascular disease among people with diabetes: the strong heart study..  Cardiovascular diabetology.  21:-. 2022
• Vitamin D supplementation in children and young adults with persistent proteinuria secondary to glomerular disease..  Pediatric nephrology (Berlin, Germany).  38:749-756. 2022
• Circulating Ceramides and Sphingomyelins and Risk of Mortality: The Cardiovascular Health Study..  Clinical chemistry.  67:1650-1659. 2021
• Plasma ceramides containing saturated fatty acids are associated with risk of type 2 diabetes..  Journal of lipid research.  -. 2021
• Plasma Ceramide Species Are Associated with Diabetes Risk in Participants of the Strong Heart Study..  The Journal of nutrition.  150:1214-1222. 2020
• Plasma Ceramides and Sphingomyelins in Relation to Atrial Fibrillation Risk: The Cardiovascular Health Study..  Journal of the American Heart Association.  9:-. 2020
• Plasma Ceramides and Sphingomyelins in Relation to Heart Failure Risk..  Circulation. Heart failure.  12:-. 2019
• Circulating sphingolipids, fasting glucose, and impaired fasting glucose: The Strong Heart Family Study..  EBioMedicine.  44-49. 2018
• Circulating Sphingolipids, Insulin, HOMA-IR, and HOMA-B: The Strong Heart Family Study..  Diabetes.  67:1663-1672. 2018